{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001176309","name":"ORAMED PHARMACEUTICALS INC.","summary":"Oramed Pharmaceuticals is a pharmaceutical company focused on research and development of oral delivery of therapeutic proteins, including oral insulin, using its proprietary POD technology platform. Beyond core pharma R&D, Oramed makes strategic investments in healthcare and life sciences companies, including Scilex Holding Company, Alpha Tau Medical, BioXcel Therapeutics, and joint venture OraTech, to complement its long-term business objectives.","people":[],"products":[{"name":"Oral Insulin (POD Technology)","type":"platform","description":"Oral dosage form designed to deliver active insulin or other proteins through the gastrointestinal tract without chemically modifying them."},{"name":"ZTLido (via RoyaltyVest)","type":"service","description":"Lidocaine topical system 1.8% licensed for development and commercialization outside the United States through joint venture RoyaltyVest."},{"name":"Gloperba/Elyxyb Royalties","type":"service","description":"Royalty rights on worldwide net sales of Gloperba and Elyxyb products acquired through Tranche B Note Consent arrangement."}],"partnerships":[{"partner_name":"Hefei Tianhui Biotech Co., Ltd. (HTIT)","partnership_type":"development","description":"Joint venture agreement to develop and commercialize oral insulin combining Oramed technology with HTIT manufacturing; subsequently terminated October 2025.","start_date":null},{"partner_name":"Scilex Holding Company","partnership_type":"strategic","description":"Series of financing, note, royalty, and warrant transactions including Tranche A and Tranche B Notes and royalty purchase agreements.","start_date":null},{"partner_name":"Alpha Tau Medical Ltd.","partnership_type":"strategic","description":"Share purchase and services agreement; Oramed invested ~$38.2M, holds ~17% of Alpha Tau and provides investor/PR services.","start_date":null},{"partner_name":"RoyaltyVest Ltd.","partnership_type":"strategic","description":"Joint venture with institutional investors to license and commercialize ZTLido and related lidocaine products outside the United States.","start_date":null},{"partner_name":"BioXcel Therapeutics, Inc.","partnership_type":"strategic","description":"Investment via RoyaltyVest in registered direct offering acquiring shares and warrants for $14,000,000 total consideration.","start_date":null}],"affiliations":[],"origin":{"leaf":"5ec30fb726e1782b787c507edd25d9c93096e540cf461433a83ee0bb8feffdbf","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"bb05676d1a63b2c127d7d55a0e4ccbccfd940e51c057a5f451d936675e630784","parent":"cea5254b81b972db426f1b2eb56b601d4d2afb8e1473eea9983748de2a4ce826","source":"0001213900-26-034835","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}